Back to Search
Start Over
Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens.
- Source :
- Annals of Hematology; Feb2022, Vol. 101 Issue 2, p465-467, 3p
- Publication Year :
- 2022
-
Abstract
- Dear Editor, Daratumumab (Dara)-combination regimens have shown promising outcomes for patients with newly diagnosed multiple myeloma (NDMM) or relapsed and refractory multiple myeloma (RRMM). These patients (median age = 61 years; range = 46-75) were treated as follows: Dara/bortezomib/dexamethasone ( I n i = 13), Dara/lenalidomide/dexamethasone ( I n i = 1), and Dara/bortezomib/melphalan/prednisone ( I n i = 1). [Extracted from the article]
- Subjects :
- MULTIPLE myeloma
KILLER cells
CYTOMEGALOVIRUSES
Subjects
Details
- Language :
- English
- ISSN :
- 09395555
- Volume :
- 101
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Annals of Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 154567462
- Full Text :
- https://doi.org/10.1007/s00277-021-04525-9